Management of hyperglycaemia in type 2 diabetes

被引：53

作者：

Heine, R. J.

Diamant, M.

Mbanya, J-C

Nathan, D. M.

机构：

[1] VU Univ Med Ctr Amsterdam, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands

[2] Univ Yaounde, Dept Internal Med & Specialties, Diabet & Endocrine Unit, Yaounde, Cameroon

[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA USA

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2006年 / 333卷 / 7580期

关键词：

D O I：

10.1136/bmj.39022.462546.80

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1200 / 1204A

页数：6

共 30 条

[1]

*AM DIAB ASS, 2005, DIABETES CARE S1, V28, pS15

[2]

[Anonymous], 1999, Diabet Med, V16, P716

[3] Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes [J].

Cook, MN ;

Girman, CJ ;

Stein, PP ;

Alexander, CM ;

Holman, RR .

DIABETES CARE, 2005, 28 (05) :995-1000

[4] EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].

DEFRONZO, RA ;

GOODMAN, AM ;

ABELOVE, W ;

REID, E ;

PITA, J ;

CALLAHAN, M ;

JOHNSON, D ;

PELAYO, E ;

PUGH, J ;

SHANK, M ;

GARZA, P ;

HAAG, B ;

KORFF, J ;

ANGELO, A ;

IZENSTEIN, B ;

VANDERLEEDEN, M ;

CATHCART, H ;

TIERNEY, M ;

BIGGS, D ;

KARAM, J ;

NOLTE, M ;

GAVIN, L ;

ELDER, MA ;

CORBOY, J ;

THWAITE, D ;

WONG, S ;

DAVIDSON, M ;

PETERS, A ;

DUNCAN, T ;

KERCHER, S ;

FISCHER, J ;

KIPNES, M ;

RADNICK, BJ ;

ROURA, M ;

ROQUE, J ;

MONTGOMERY, C ;

COLLUM, P ;

RUST, M ;

POHL, S ;

PFEIFER, M ;

ALLWEISS, P ;

LEICHTER, S ;

LEACH, P ;

GALLINA, D ;

MUSEY, V ;

BERKOWITZ, K ;

EASTMAN, R ;

TAYLOR, T ;

DELAPENA, MS ;

ZAWADSKI, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549

[5] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[6] Biologic actions and therapeutic potential of the proglucagon-derived peptides [J].

Drucker, DJ .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (01) :22-31

[7] SULFONYLUREAS IN NIDDM [J].

GROOP, LC .

DIABETES CARE, 1992, 15 (06) :737-754

[8]

Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006

[9] Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005 [J].

Holst, JJ .

DIABETOLOGIA, 2006, 49 (02) :253-260

[10] Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide [J].

Holstein, A ;

Plaschke, A ;

Egberts, EH .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (06) :467-473

← 1 2 3 →